1. Pfizer and BioNTech submitted an emergency use authorization request to the FDA on April 26 for a COVID-19 vaccine booster for children ages 5-11.
2. Pfizer and French biotech company Valneva reported their Lyme disease vaccine candidate works better in children than in adults.
3. Pfizer recalled five lots of Accupril, a hypertension drug, April 22 due to the presence of a compound that may increase cancer risk.
4. Pfizer appointed David Denton its new CFO on April 11.
5. Pfizer is set to acquire ReViral, a drugmaker focusing on respiratory syncytial virus therapeutics, for $525 million.
6. Pfizer on March 21 issued a voluntary recall of its hypertension drug Accuretic and two generic versions of the drug because of elevated levels of a nitrosamine called N-nitroso-quinapril.
7. Pfizer and its partner, BioNTech, submitted an application to the FDA seeking emergency authorization for a second booster shot of their COVID-19 vaccine for people 65 and older, the company said March 15.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
